(+)-Dihydrexidine hydrochloride | 137417-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (+)-Dihydrexidine hydrochloride
• 英文别名: (6aR,12bS)-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride；trans-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol hydrochloride；Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo [a]phenanthridine hydrochloride；dihydrexidine；Dihydrexidine hydrochloride；(6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol;hydrochloride
• CAS: 137417-08-4
• 化学式: C₁₇H₁₇NO₂*ClH
• 分子量: 303.788
• InChiKey: IJYUPBNUPIRQEP-SATBOSKTSA-N

物化性质

• 溶解度：
  在水中溶解度为 10 mM，在 DMSO 中溶解度为 50 mM

计算性质

• 辛醇/水分配系数(LogP)：
  3.07
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  57.1
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(3,4-dimethoxyphenyl)-1-phenyl-1-butene 在 4-甲氧基苯硫酚 、 三氟甲磺酸三甲基硅酯 、 三氟化硼乙醚 、 三溴化硼 、 copper(II) bis(trifluoromethanesulfonate) 、 碳酸氢钠 、 potassium carbonate 、 (R,R)-2,2'-异亚丙基双(4-苯基-2-恶唑啉) 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 33.0h， 生成 (+)-Dihydrexidine hydrochloride
  参考文献：
  名称：

  Asymmetric synthesis of the dopamine D1 agonist, dihydrexidine

  摘要：

  A concise asymmetric synthesis of first, high affinity domaine D1 full agonist, dihydrexidine has been accomplished via catalytic enantioselective aziridination and subsequent one-pot Friedel-Crafts cyclization of an in situ generated tethered aziridine with high diastereo- and enantioselectivities. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2011.04.008

文献信息

• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• A Novel and Efficient Synthesis of Dihydrexidine
  作者：David Nichols、Juan Cueva

  DOI：10.1055/s-0028-1083359

  日期：——

  efficient synthesis of the dopamine D1 selective full agonist dihydrexidine has been achieved in high yields and requiring no chromatographic separations via a facilitated intramolecular Henry cyclization of a (nitropropyl)benzophenone and subsequent diastereomerically selective reduction of the resulting tricyclic nitroalkene. acylations - intramolecular Henry reaction - nitroalkene - total synthesis.

  高产率地实现了多巴胺D 1选择性全激动剂二氢己定的有效合成，并且不需要通过（硝基丙基）二苯甲酮的分子内亨利环化和随后的非对映异构选择性还原得到的三环硝基烯而进行色谱分离。 酰化-分子内Henry反应-硝基烯烃-全合成。
• Co-Administration of Dopamine-Receptor Binding Compounds
  申请人：Fernandes Prabhavathi B.

  公开号：US20100041690A1

  公开（公告）日：2010-02-18

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist, Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗神经、精神和精神障碍患者的方法，包括向患者施用部分和/或完全的多巴胺D1受体激动剂的有效剂量，并向患者施用多巴胺D2受体拮抗剂的有效剂量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以在同一组合物或不同组合物中向患者施用。
• OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR
  申请人：Nichols David E.

  公开号：US20120041018A1

  公开（公告）日：2012-02-16

  Octahydrobenzoisoquinoline modulators of dopamine receptors are described herein. Methods for using octahydrobenzoisoquinoline modulators of dopamine receptors in the treatment of dopamine dysfunction are also described herein.

  本文描述了八氢苯并异喹啉多巴胺受体调节剂。本文还描述了使用八氢苯并异喹啉多巴胺受体调节剂治疗多巴胺功能障碍的方法。
• Method for post mortem diagnosis of Alzheimer's Disease (AD)
  申请人：Red Bull GmbH

  公开号：EP2806276A1

  公开（公告）日：2014-11-26

  Disclosed is a method for diagnosing Alzheimer's Disease (AD) post mortem, wherein the amount of at least one receptor complex, selected from the group consisting of nicotinic acetylcholine receptor complex 4, nicotinic acetylcholine receptor complex 7, dopamine receptor complex D1 and dopamine receptor complex D2, is measured in a brain sample of a patient and diagnosing AD, if the amount of the complex in the sample is increased compared to normal, non-AD levels.

  本发明公开了一种用于死后诊断阿尔茨海默病（AD）的方法，该方法测量患者脑样本中至少一种受体复合物的含量，这些受体复合物选自由烟碱乙酰胆碱受体复合物 4、烟碱乙酰胆碱受体复合物 7、多巴胺受体复合物 D1 和多巴胺受体复合物 D2 组成的组，如果样本中的复合物含量与正常非 AD 水平相比有所增加，则诊断为 AD。